• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

July 16, 2018

Value-Based Insurance Improves Cost-Related Patient Adherence Issues

Author(s):

Gina Kokosky, Assistant Editor

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.

Poor medication adherence resulting from missed doses, delayed prescription refills, or the lack of any refills is often associated with the cost of a prescription. It has previously been found that the more a patient pays out-of-pocket for a prescription, the less likely that patient is to be adherent.

Targeting cost with a value-based insurance design (VBID) may be the solution to cost-related adherence issues, according to a study published by Health Affairs. Insurance plans that operate by charging patients less for the most beneficial medicines, and potentially making some medicine free to patients with certain conditions, can be an effective method, according to the study authors.

The VBID plans were shown to improve adherence among patients without increasing the cost of insuring a patient. Although drug costs grew for insurers, the total price of insurance remained the same, which suggests that improved adherence results in less spending on other health care, according to the study.

"Enhanced access to high-value drugs that did not lead to an increase in total spending is a win/win for both insurers and patients," Mark Fendrick, MD, senior author, said in a press release. "If total costs are equal, using more medicines that prevent costly hospitalizations is clearly preferable to having people being admitted to a hospital."

The authors thoroughly examined 21 studies from the past 10 years assessing VBID prescription drug plans compared with standard plans. Each study was measured to a high standard based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.

Insurance plans with VBID-style co-pays and co-insurance were reviewed in comparison with standard plans. Out-of-pocket payments were reduced in the VBID-style plans for prescriptions that are considered high-value to patients with certain conditions. Drugs used for long-term prevention in high-risk patients, including patients with diabetes, high blood pressure, high cholesterol, and asthma, were prioritized in the study, according to the researchers.

Related Coverage: Adherence Lacking to High-Cost Multiple Sclerosis Disease-Modifying Drugs

The authors measured the impact of reduced out-of-pocket costs on adherence by comparing the amount of medication obtained to the length of the prescription, according to the study. The authors also took health care spending, use of health care services, clinical outcomes, and quality of care from the studies into account.

With a VBID model, patients who used diabetes medications had a significant improvement in patient adherence. The authors noted, however, that diabetes management programs may be partially responsible for the drastic increase.

Most of the studies on blood pressure medication and all of the studies on cholesterol-lowering statins showed an improvement in adherence with a VBID plan, according to the study. Only 2 of the 5 studies on asthma medication adherence with a VBID plan showed improvement.

The authors looked at 9 studies on overall health care spending for patients with a VBID plan, most of which showed an increase in spending on prescription drugs for insurers, while 3 studies showed a significant decrease in out-of-pocket costs for patients.

The studies suggest that the increase in drug spending was offset by decreased spending in other areas of health care, such as hospital visits, the researchers noted. Insurers experienced a reduced cost for patients with a VBID-style plan in 2 cases, while the other 7 cases showed no change in cost for insurers, according to the study.

The assessment did not provide any substantial evidence on patient outcomes or quality of care from a VBID-style plan. The authors noted that future studies need to focus on examining the long-term patient outcomes associated with a VBID-style plan.

References

Agarwal R, Gupta A, Fendrick AM. Value-based insurance design improves medication adherence without an increase in total health care spending. Health Affairs. 2018.

https://doi.org/10.1377/hlthaff.2017.1633.

Pay Less, Take More: Success in Getting Patients to Take Their Medicine [news release]. University of Michigan’s website. http://ihpi.umich.edu/news/pay-less-take-more-success-getting-patients-take-their-medicine. Accessed July 11, 2018.

Related Videos
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Microscopic View of Hematological Slide Showing Thrombocytopenia and Low Platelet Count in Blood
May 31st 2025

IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Image depicting kidney affected by CKD -- Image credit: Crystal light | stock.adobe.com
May 30th 2025

Cellular Senescence is a Central Driver of Chronic Kidney Disease-Related Kidney Fibrosis

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Model of a kidney depicting CKD -- Image credit: kanruthai | stock.adobe.com
May 29th 2025

Childhood Cancer Survivors at an Increased Risk of Developing CKD, Study Finds

Gillian McGovern, Associate Editor
Prague, Czech Republic - August 28 2024: STELARA box with USTEKINUMAB active substance by JANSSEN, used for psoriasis, Crohn’s disease, and ulcerative colitis.
May 28th 2025

FDA Approves Ustekinumab-hmny Injection, a Biosimilar Referencing Stelara

Luke Halpern, Assistant Editor
Related Content
Advertisement
Microscopic View of Hematological Slide Showing Thrombocytopenia and Low Platelet Count in Blood
May 31st 2025

IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Image depicting kidney affected by CKD -- Image credit: Crystal light | stock.adobe.com
May 30th 2025

Cellular Senescence is a Central Driver of Chronic Kidney Disease-Related Kidney Fibrosis

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Model of a kidney depicting CKD -- Image credit: kanruthai | stock.adobe.com
May 29th 2025

Childhood Cancer Survivors at an Increased Risk of Developing CKD, Study Finds

Gillian McGovern, Associate Editor
Prague, Czech Republic - August 28 2024: STELARA box with USTEKINUMAB active substance by JANSSEN, used for psoriasis, Crohn’s disease, and ulcerative colitis.
May 28th 2025

FDA Approves Ustekinumab-hmny Injection, a Biosimilar Referencing Stelara

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.